Published in Bone on December 01, 2001
Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med (2009) 4.39
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res (2009) 1.84
The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest (2002) 1.59
Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor. Am J Pathol (2009) 1.03
Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice. Endocrinology (2011) 1.01
Modeling the benefits of pamidronate in children with osteogenesis imperfecta. J Clin Invest (2002) 1.01
The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br J Pharmacol (2005) 0.95
Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility. Ther Clin Risk Manag (2012) 0.90
Mammalian hibernation as a model of disuse osteoporosis: the effects of physical inactivity on bone metabolism, structure, and strength. Am J Physiol Regul Integr Comp Physiol (2008) 0.88
Bisphosphonates and bone quality. Bonekey Rep (2014) 0.85
Synthesis, characterization and osteoconductivity properties of bone fillers based on alendronate-loaded poly(ε-caprolactone)/hydroxyapatite microspheres. J Mater Sci Mater Med (2011) 0.83
Effect of alendronate on endochondral ossification in mandibular condyles of growing rats. Eur J Histochem (2012) 0.83
Histomorphometric interpretation of bone biopsies for the evaluation of osteoporosis treatment. Bonekey Rep (2012) 0.82
Bisphosphonate therapy in pediatric patients. J Diabetes Metab Disord (2014) 0.81
Bisphosphonates and cancer: what opportunities from nanotechnology? J Drug Deliv (2013) 0.81
Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells. Biochem Pharmacol (2012) 0.80
The role of muscle loading on bone (Re)modeling at the developing enthesis. PLoS One (2014) 0.79
Ligand-modified aminobisphosphonate for linking proteins to hydroxyapatite and bone surface. Bioconjug Chem (2007) 0.79
Altered macrophagic THP-1 cell phagocytosis and migration in bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clin Oral Investig (2015) 0.78
Effect of bisphosphonates on orthodontic tooth movement-an update. J Clin Diagn Res (2015) 0.78
Effects of drug discontinuation after short-term daily alendronate administration on osteoblasts and osteocytes in mice. Histochem Cell Biol (2016) 0.78
Induction of creatine kinase release from cultured osteoclasts via the pharmacological action of aminobisphosphonates. Springerplus (2015) 0.77
Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality. BMC Musculoskelet Disord (2010) 0.77
Distinctive tooth-extraction socket healing: bisphosphonate versus parathyroid hormone therapy. J Periodontol (2013) 0.77
Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporos Int (2004) 0.77
Non-Lethal Type VIII Osteogenesis Imperfecta Has Elevated Bone Matrix Mineralization. J Clin Endocrinol Metab (2016) 0.75
Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders. Clin Cases Miner Bone Metab (2007) 0.75
Giant osteoclasts in patients under bisphosphonates. BMC Clin Pathol (2014) 0.75
Effect of zoledronate on the responses of osteocytes to acute parathyroid hormone. Calcif Tissue Int (2013) 0.75
Role of osteoblasts in hormonal control of bone resorption--a hypothesis. Calcif Tissue Int (1981) 3.77
Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J (1994) 3.60
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A (1999) 2.66
Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest (1991) 2.63
Parathyroid hormone-responsive clonal cell lines from rat osteosarcoma. Endocrinology (1980) 2.46
Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol (1992) 2.09
Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res (1999) 2.06
Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res (1987) 2.03
Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone (2001) 1.94
Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells. J Clin Invest (1983) 1.84
M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ (2003) 1.83
Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys (2000) 1.82
PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. J Clin Invest (1998) 1.74
Expression of a calcium-mobilizing parathyroid hormone-like peptide in lactating mammary tissue. Science (1988) 1.64
Tissue specificity and developmental expression of rat osteopontin. Biochem Biophys Res Commun (1987) 1.61
Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest (1994) 1.57
High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells. J Bone Miner Res (1998) 1.56
Different pattern of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization. J Bone Miner Res (1990) 1.52
The effect of 1,25(OH)2D3 on alkaline phosphatase in osteoblastic osteosarcoma cells. J Biol Chem (1982) 1.45
Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins. Cell Death Differ (2004) 1.44
Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. J Cell Sci (1999) 1.38
Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem (1999) 1.38
Human renal carcinoma expresses two messages encoding a parathyroid hormone-like peptide: evidence for the alternative splicing of a single-copy gene. Proc Natl Acad Sci U S A (1988) 1.36
Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein. Endocrinology (1993) 1.35
Prostaglandin receptor EP(4) mediates the bone anabolic effects of PGE(2). Mol Pharmacol (2001) 1.35
The effect of hemopoietic growth factors on the generation of osteoclast-like cells in mouse bone marrow cultures. Endocrinology (1990) 1.32
Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type beta transforming growth factor. J Biol Chem (1988) 1.32
Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res (1996) 1.31
Msx-2/Hox 8.1: a transcriptional regulator of the rat osteocalcin promoter. Mol Endocrinol (1994) 1.29
Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone (1996) 1.26
Mutations in the cytoplasmic domain of the integrin beta1 chain indicate a role for endocytosis factors in bacterial internalization. J Biol Chem (1996) 1.26
Pattern of gene expression following rat tibial marrow ablation. J Bone Miner Res (1993) 1.25
Characterization of the rat osteocalcin gene: stimulation of promoter activity by 1,25-dihydroxyvitamin D3. Biochemistry (1988) 1.24
Type beta transforming growth factor (TGF beta) regulation of alkaline phosphatase expression and other phenotype-related mRNAs in osteoblastic rat osteosarcoma cells. J Cell Physiol (1987) 1.22
Integrins and signaling in osteoclast function. Matrix Biol (2000) 1.21
Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): positive correlation with the presence of the GH-induced IGF-binding protein BP-3. Endocrinology (1990) 1.21
The alphavbeta3 integrin regulates alpha5beta1-mediated cell migration toward fibronectin. J Biol Chem (1997) 1.20
Glucocorticoid regulation of alkaline phosphatase in the osteoblastic osteosarcoma cell line ROS 17/2.8. Endocrinology (1985) 1.20
Osteopenia in the immobilized rat hind limb is associated with increased bone resorption and decreased bone formation. Bone (1989) 1.18
Convergence of alpha(v)beta(3) integrin- and macrophage colony stimulating factor-mediated signals on phospholipase Cgamma in prefusion osteoclasts. J Cell Biol (2001) 1.15
Opposing effects of fibroblast growth factor and pertussis toxin on alkaline phosphatase, osteopontin, osteocalcin, and type I collagen mRNA levels in ROS 17/2.8 cells. J Biol Chem (1989) 1.14
Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A (1996) 1.14
Integrin function in osteoclasts. J Endocrinol (1997) 1.14
In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology (2000) 1.14
Evidence for preferential effects of parathyroid hormone, calcitonin and adenosine on bone and periosteum. Endocrinology (1977) 1.13
Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol (2001) 1.12
Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells. Endocrinology (1998) 1.11
Stable association of PYK2 and p130(Cas) in osteoclasts and their co-localization in the sealing zone. J Biol Chem (1999) 1.08
Type-beta transforming growth factor inhibits proliferation and expression of alkaline phosphatase in murine osteoblast-like cells. Biochem Biophys Res Commun (1986) 1.07
PYK2 is an adhesion kinase in macrophages, localized in podosomes and activated by beta(2)-integrin ligation. Cell Motil Cytoskeleton (2000) 1.07
Inhibition of osteoclast function by adenovirus expressing antisense protein-tyrosine kinase 2. J Biol Chem (2000) 1.07
Activity of the rat osteocalcin basal promoter in osteoblastic cells is dependent upon homeodomain and CP1 binding motifs. Mol Endocrinol (1994) 1.07
Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology (1989) 1.06
Abnormal localisation and hyperclustering of (alpha)(V)(beta)(3) integrins and associated proteins in Src-deficient or tyrphostin A9-treated osteoclasts. J Cell Sci (2001) 1.05
Tyrosine phosphorylation of p130Cas is involved in actin organization in osteoclasts. J Biol Chem (1998) 1.04
Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone. J Cell Biol (1989) 1.03
cDNA cloning of alkaline phosphatase from rat osteosarcoma (ROS 17/2.8) cells. J Bone Miner Res (1987) 1.03
High lateral mobility of endogenous and transfected alkaline phosphatase: a phosphatidylinositol-anchored membrane protein. J Cell Biol (1987) 1.02
Membrane changes during cartilage maturation. Increase in 5'-nucleotidase and decrease in adenosine inhibition of adenylate cyclase. J Cell Biol (1977) 1.02
Isolation and characterization of highly enriched, prefusion mouse osteoclastic cells. Exp Cell Res (1995) 1.01
Biphasic effects of transforming growth factor-beta on the production of osteoclast-like cells in mouse bone marrow cultures: the role of prostaglandins in the generation of these cells. Endocrinology (1990) 1.01
The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology (1998) 1.01
Alkaline phosphatase inhibition by parathyroid hormone and isoproterenol in a clonal rat osteosarcoma cell line. Possible mediation by cyclic AMP. Calcif Tissue Int (1982) 1.00
Direct effects of 17 beta-estradiol on trabecular bone in ovariectomized rats. Proc Natl Acad Sci U S A (1990) 1.00
Functional estrogen receptors in osteoblastic cells demonstrated by transfection with a reporter gene containing an estrogen response element. Mol Endocrinol (1991) 0.99
Sphingosine kinase mediates cyclic AMP suppression of apoptosis in rat periosteal cells. Mol Pharmacol (1998) 0.99
Differential expression of insulin-like growth factor-I (IGF-I) and IGF-II messenger ribonucleic acid in growing rat bone. Endocrinology (1993) 0.99
The effect of parathyroid hormone and thyrocalcitonin on the accumulation of cyclic adenosine 3':5'-monophosphate in freshly isolated bone cells. J Biol Chem (1974) 0.99
Impaired bone activity in aged rats: alterations at the cellular and molecular levels. Bone (1992) 0.97
NER, a new member of the gene family encoding the human steroid hormone nuclear receptor. Gene (1994) 0.96
Epiphyseal cartilage cAMP changes produced by electrical and mechanical perturbations. Clin Orthop Relat Res (1977) 0.96
Bone resorptive factor produced by osteosarcoma cells with osteoblastic features is PGE2. Biochem Biophys Res Commun (1981) 0.96
Soluble alpha v beta 3-integrin ligands raise [Ca2+]i in rat osteoclasts and mouse-derived osteoclast-like cells. Am J Physiol (1994) 0.95
Rat calvarial cell lines immortalized with SV-40 large T antigen: constitutive and retinoic acid-inducible expression of osteoblastic features. Endocrinology (1989) 0.95
Interrelationships between Ca2+ and adenylate and guanylate cyclases in the control of platelet secretion and aggregation. Proc Natl Acad Sci U S A (1976) 0.95
Integrin-mediated signaling in the regulation of osteoclast adhesion and activation. Front Biosci (1998) 0.94
Effects of acidic and basic fibroblast growth factors on osteoblastic cells. Connect Tissue Res (1989) 0.94
Growth stimulation of rat calvaria osteoblastic cells by acidic fibroblast growth factor. Endocrinology (1987) 0.94
Alkaline phosphatase as a reporter enzyme. Gene (1988) 0.94
Phosphatidylinositol 3-kinase association with the osteoclast cytoskeleton, and its involvement in osteoclast attachment and spreading. Exp Cell Res (1997) 0.94
Indomethacin inhibition of tenotomy-induced bone resorption in rats. J Bone Miner Res (1988) 0.93
Cyclic AMP and cyclic GMP: mediators of the mechanical effects on bone remodeling. Science (1975) 0.93
Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor. J Biol Chem (1996) 0.92
Leukemia inhibitory factor suppresses proliferation, alkaline phosphatase activity, and type I collagen messenger ribonucleic acid level and enhances osteopontin mRNA level in murine osteoblast-like (MC3T3E1) cells. Endocrinology (1990) 0.92
Retinoic acid increases zif268 early gene expression in rat preosteoblastic cells. Mol Cell Biol (1991) 0.92
Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodontal Res (1994) 0.91
Expression of alpha v and beta 3 integrin subunits in rat osteoclasts in situ. J Bone Miner Res (1993) 0.91
Thionapthene-2-carboxylic acid: a new antihypercalcemic agent. Endocrinology (1985) 0.91
Cyclic AMP-mediated stabilization of osteocalcin mRNA in rat osteoblast-like cells treated with parathyroid hormone. J Biol Chem (1988) 0.91
Cross-hybridization and relationships of various papillomavirus DNAs at different degrees of stringency. Intervirology (1987) 0.90
Type beta transforming growth factor regulates expression of genes encoding bone matrix proteins. Connect Tissue Res (1989) 0.90
The role of prostaglandins in bone formation. Connect Tissue Res (1995) 0.90
Direct action of the parathyroid hormone-like human hypercalcemic factor on bone. Proc Natl Acad Sci U S A (1988) 0.90
Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year study. J Clin Invest (1995) 0.90
Osteogenic protein-1 up-regulation of the collagen X promoter activity is mediated by a MEF-2-like sequence and requires an adjacent AP-1 sequence. Mol Endocrinol (1997) 0.90